Drug Combination Details
| General Information of the Combination (ID: C36985) | |||||
|---|---|---|---|---|---|
| Name | Epigallocatechin gallate NP Info | + | Bortezomib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Multiple myeloma
[ICD-11: 2A83]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression and phosphorylation | RELA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | KM-3 | CVCL_0011 | Multiple myeloma | Homo sapiens | ||
| Experimental
Result(s) |
Combined EGCG and bortezomib showed synergistic anticancer effect partly via regulating NF-kappaB pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. Acta Biochim Biophys Sin (Shanghai). 2009 Dec;41(12):1018-26. | |||
